09:10 AM EDT, 05/21/2024 (MT Newswires) -- Health care stocks were steady premarket Tuesday, with the the Health Care Select Sector SPDR Fund ( XLV ) was down a slight 0.1% and the iShares Biotechnology ETF ( IBB ) recently unchanged.

Larimar Therapeutics ( LRMR ) was rallying past 13% after saying the US Food and Drug Administration lifted a partial clinical hold previously imposed on the clinical program to study nomlabofusp for treating Friedreich's Ataxia, an inherited nervous system disorder.

AstraZeneca ( AZN ) was up 0.7% after saying it is targeting total revenue of $80 billion by 2030, up from $45.8 billion in 2023, through portfolio expansion and the expected launch of 20 new medicines before the decade ends.

Eli Lilly's ( LLY ) tirzepatide injection was approved for the treatment of adults with type 2 diabetes in China, media reports said. Eli Lilly ( LLY ) was 0.6% higher pre-bell.